Trump drops Biden’s proposal for Medicare to cover obesity drugs like Wegovy and Zepbound

Trump drops Biden’s proposal for Medicare to cover obesity drugs like Wegovy and Zepbound


A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, made by Novo Nordisk. 

Reuters

President Donald Trump on Friday dropped a Biden administration proposal to have Medicare cover obesity drugs, including popular but costly GLP-1 treatments such as Novo Nordisk‘s Wegovy and Eli Lilly‘s Zepbound.

But the Centers for Medicare and Medicaid Services said it may reconsider coverage of those drugs in the future, according to a fact sheet on the rule.

The proposal would have given millions more Americans access to those drugs, but would have cost the government billions. Many health plans, including Medicare, don’t currently cover weight loss treatments, and some patients simply can’t afford their hefty price tags before insurance.

Wegovy and Zepbound both cost roughly $1,000 before insurance and other rebates. Allowing Medicare to cover those drugs and other weight loss medications could cost $35 billion over nine years, a congressional analysis found.

Under the Biden administration’s proposal, only those who are considered obese — someone who has a body mass index of 30 or higher — would qualify for coverage. Some people may already get coverage of the drugs through Medicare or Medicaid if they have diabetes or are at risk for stroke or heart disease.

The rule wasn’t finalized before Trump took office.

Novo Nordisk and Eli Lilly did not immediately respond to requests for comment.

Shares of Lilly fell more than 2% in extended trading, while Novo Nordisk’s stock dropped more than 1%.



Source

Healthy Returns: A key step forward for Novo Nordisk’s GLP-1 pill
Health

Healthy Returns: A key step forward for Novo Nordisk’s GLP-1 pill

Novo Nordisk flags flutter outside their office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, July 14, 2025. Tom Little | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. A closely watched pill from […]

Read More
Why U.S. cattle ranchers say Trump’s Argentine beef import talk is no solution to domestic food supply threat
Health

Why U.S. cattle ranchers say Trump’s Argentine beef import talk is no solution to domestic food supply threat

Cattle detained in the pens of the Chihuahua Regional Livestock Union , at the Jeronimo-Santa Teresa border crossing in Ciudad Juarez, Mexico on November 27, 2024, after the United States stopped imports of Mexican cattle due to the presence of screwworm. Anadolu | Anadolu | Getty Images Cattle ranchers in Texas and around the country […]

Read More
Anthropic launches Claude Life Sciences to give researchers an AI efficiency boost
Health

Anthropic launches Claude Life Sciences to give researchers an AI efficiency boost

Dario Amodei, Anthropic CEO, speaking on CNBC’s Squawk Box outside the World Economic Forum in Davos, Switzerland on Jan. 21st, 2025. Gerry Miller | CNBC Anthropic on Monday announced Claude for Life Sciences, a new offering for researchers to use the company’s artificial intelligence technology in the advancement of scientific discovery.  Claude for Life Sciences is […]

Read More